Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout
Daiichi Arbitration Is Another Wildcard
The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.
You may also be interested in...
Full data presented at ESMO from a closely watched trial of Seagen/Astellas’s Padcev and Merck & Co’s Keytruda should support regulatory approval of the combination in cisplatin-ineligible first-line metastatic urothelial cancer patients but concerns over duration of treatment remain.
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.